Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorMahidol University
About this trial
A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy
Eligibility criteria
Qualifiers
histologically confirmed cancer patients who will be started on first dose of oxaliplatin, irinotecan or carboplatin
age of >18 years old
Disqualifiers
pregnancy or breast feeding
has emetic episode within 24 hours
gut obstruction
uncontrolled brain metastasis
Trial design
Treatments tested in this trial
- olanzapine
- Placebo
Treatment groups
140 Participants
are divided into 2 treatment groupsLocations
1Faculty of Medicine Siriraj Hospital, Mahidol University10700, BangkokBangkok, Thailand
Sponsors and collaborators
Mahidol University
Lead sponsor
Source ClinicalTrials.gov